Xceleron expands US operation with multimillion dollar investment in new facilities
Xceleron announced a new multimillion dollar investment to create its first pharmaceutical testing facilities in the U.S. With up to 50% of global demand for drug and metabolite analysis coming from the U.S. Xceleron will invest up to $7.5m on the purchase of a new accelerator mass spectrometer (AMS) to carry out analysis on pharmaceutical drug candidates, new laboratories in Maryland and additional personnel. The new facilities shall come on stream in late 2007, considerably increasing the company's testing capacity. By 2011 employee numbers are planned to rise to at least 150 and North American revenues to exceed $20m.
According to the company, Xceleron is the only good laboratory practice (GLP) accredited biomedical facility in the world with unique expertise in the field of zeptobiology (ultra-sensitive drug and metabolite analysis) using AMS. AMS enables the pharmacokinetic (PK) measurement of absorption, distribution, metabolism and excretion of drugs administered to humans in microdose quantities. The company's approach facilitates Phase 0 early human trials to identify the metabolic fate of a drug at the single molecule level.
Organizations
Other news from the department business & finance
These products might interest you

Stellar Mass Spectrometer by Thermo Fisher Scientific
High-Sensitivity Mass Spectrometer for Fast Biomarker Validation
Boost lab efficiency with 10x improved quantitation and multi-analyte automation

BIOS ANALYTIQUE - Soluciones de Renting y Leasing para laboratorios by Bios Analytique
Specialists in the rental and leasing of scientific equipment for laboratories throughout Europe
Whether you have an unexpected requirement or limited budget, we have the perfect solution for you

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!

Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Last viewed contents

Seeing inside cells with an integrated nanowire probe - Real-time, in-situ sensing and tracking of cell development and maturation is achieved using a label-free nano-optical device
House_healing
William_Hunter_(anatomist)
Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
Paroxysmal_extreme_pain_disorder

Nobel laureate Günter Blobel dies at age 81 - He redefined cell biology by discovering signal peptides in proteins
Compugen Announces Discovery of Abundant RNA Editing Sites in the Human Transcriptome - Findings published in Nature Biotechnology

Merck and Pfizer Initiate Phase III Study with Avelumab in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer
Lonza and BioWa sign license agreements with Pfizer
